What is ArcticZymes Technologies ASA OCF Margin %?
ArcticZymes Technologies ASALTS:0DRV 76 OCF Margin % is 0.65% as of Mar. 2026, which is 96% below its 10-year median of 14.66. GuruFocus rates LTS:0DRV with a GF Score™ of 76/100 and a GF Value™ of kr23.81 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 960 Biotechnology companies, ArcticZymes Technologies ASA ranks better than 84.79% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DRV vs VRTX, REGN, ALNY: OCF Margin % Comparison
For the Biotechnology subindustry, ArcticZymes Technologies ASA's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ArcticZymes Technologies ASA OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ArcticZymes Technologies ASA's OCF Margin % distribution charts can be found below:
* The bar in red indicates where ArcticZymes Technologies ASA's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ArcticZymes Technologies ASA (LTS:0DRV) has a OCF Margin % of 0.65% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on ArcticZymes Technologies ASA and its competitors. This is 96% below median its historical median of 14.66. According to the industry distribution chart, ArcticZymes Technologies ASA ranks #146 out of 960 companies in the Biotechnology industry, placing it in the top 15.2%.
Is ArcticZymes Technologies ASA's OCF Margin % too high?
ArcticZymes Technologies ASA's current OCF Margin % of 0.65% is 96% below median its 10-year median of 14.66. Based on the distribution chart, ArcticZymes Technologies ASA ranks #146 out of 960 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ArcticZymes Technologies ASA has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ArcticZymes Technologies ASA's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ArcticZymes Technologies ASA ranks #146 out of 960 companies for OCF Margin %. This places ArcticZymes Technologies ASA in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on ArcticZymes Technologies ASA and its competitors. ArcticZymes Technologies ASA's current OCF Margin % is 0.65%, which is 96% below median its own 10-year median of 14.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ArcticZymes Technologies ASA stock overvalued right now?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA (LTS:0DRV) is currently considered Modestly Undervalued. The stock's GF Value™ is kr23.81, compared to a current price of kr20.90 — trading 12.2% below its estimated fair value. The current OCF Margin % is 0.65%, which is 96% below median its 10-year median of 14.66. ArcticZymes Technologies ASA's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For ArcticZymes Technologies ASA (LTS:0DRV), the current OCF Margin % is 0.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ArcticZymes Technologies ASA (LTS:0DRV) Overvalued in 2026?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA stock appears to be undervalued.
The current stock price of kr20.90 is trading 12.2% below its estimated GF Value™ of kr23.81.
GuruFocus considers ArcticZymes Technologies ASA to be Modestly Undervalued.
Key valuation signals for LTS:0DRV:
OCF Margin %: 0.65% (96% below median its 10-year median of 14.66)
GF Value™: kr23.81 vs. price of kr20.90 (12.2% below fair value)
No single metric tells the full story. See the LTS:0DRV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Norway, Germany, France, Italy, UK, Other countries in Europe, and Rest of world.
76GF Score
Get the complete analysis for LTS:0DRV
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRV has been successfully added to your 
